Latest news newssearch boxGO All Ad hoc Other 06 Jun 2023 Idorsia has entered into exclusive negotiations with regard to a prospective strategic transaction for its Asia Pacific (ex-China) operations for up to CHF 400 million 30 May 2023 Idorsia announces a change to commercial leadership 04 May 2023 Idorsia holds its Annual General Meeting of Shareholders 03 May 2023 Health Canada approves QUVIVIQ (daridorexant) for the management of adult patients with insomnia 25 Apr 2023 Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US 06 Apr 2023 Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders 17 Mar 2023 On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder 07 Feb 2023 Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company 06 Feb 2023 Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage 31 Jan 2023 Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension 09 Jan 2023 Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023 20 Dec 2022 Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension 15 Dec 2022 Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus 12 Dec 2022 Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs 05 Dec 2022 Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning 16 Nov 2022 Idorsia and Simcere enter into a licensing agreement for daridorexant in China 15 Nov 2022 QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany 13 Nov 2022 Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award 07 Nov 2022 The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension 25 Oct 2022 Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand 1 2 3 4 5 6 7
Ad hoc announcements pursuant to Art. 53 LR Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.